11
edits
Changes
STBT5:Solitary fibrous tumour (view source)
Revision as of 17:01, 27 February 2024
, 17:01, 27 February 2024→Immunophenotype
Line 53:
Line 53:
<span class="blue-text">EXAMPLE:</span> 30% (add reference)+The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span>+
+
+Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')</span>+
+
+<span class="blue-text">EXAMPLE:</span>
−
−''EGFR''; Exon 20 mutations
−
−<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
Put your text here+
|Positive (universal)||CD34
|Positive (universal)||CD34
|-
|-
−|Positive (universal)||STAT6
+|Positive (universal)||STAT6 (nuclear)
|-
|-
|Negative (universal)||
|Negative (universal)||
Line 69:
Line 69:
!Notes
!Notes
|-
|-
−|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)||<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
+|inv(12)(q13q13)||3'STAT6 / 5'NAB2||NA||55-100%
−|Yes
−|<span class="blue-text">EXAMPLE:</span> Yes
+|Unknown
−|<span class="blue-text">EXAMPLE:</span> No
+|No
−|<span class="blue-text">EXAMPLE:</span> Yes
+|Many different breakpoints in the exons and introns are associated with this fusion. Ex: ''NAB2''ex4-''STAT6''ex2; ''NAB2''ex6-''STAT6''ex16/17
−|<span class="blue-text">EXAMPLE:</span>
−|}
|}
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==
−Not Applicable
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 114:
Line 114:
|}
|}
==Characteristic Chromosomal Patterns==
==Characteristic Chromosomal Patterns==
−Not Applicable
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 141:
Line 143:
!Notes
!Notes
|-
|-
−|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
+|
−|<span class="blue-text">EXAMPLE:</span> TSG
|<span class="blue-text">EXAMPLE:</span> TSG
|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
Line 158:
Line 155:
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
==Epigenomic Alterations==
==Epigenomic Alterations==
−Not Applicable
==Genes and Main Pathways Involved==
==Genes and Main Pathways Involved==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>
Line 165:
Line 162:
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|-
−|<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations
+|NAB2::STAT6; Activating mutation
−|<span class="blue-text">EXAMPLE:</span> MAPK signaling
+|EGR Pathway
−|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
+|Increased activation of EGR1
|-
|-
|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations